Understanding Antibody-Drug Conjugates in Lung Cancer Treatment

This chapter explores the intricacies of antibody-drug conjugates (ADCs) and their variable effectiveness in non-squamous cell lung cancer, focusing on target expression and prior chemotherapy effects. It also examines the potential of artificial intelligence to improve predictions for ADC outcomes, addressing the challenges in optimizing these treatments.